Today ReNeuron released encouraging early Phase I/II efficacy data for its lead retinal cell therapy programme, Human Retinal Progenitor Cells (hRPC), demonstrating a clear visual acuity improvement in retinitis pigmentosa (RP) patients. RP is an inherited, blindness-causing degenerative eye disease, affecting approx. 100k patients in the US. For the vast majority of RP patients there is currently no treatment available, and there is a clear unmet need for a treatment to reverse disease progress ....
20 Feb 2019
Encouraging preliminary Phase I/II data in retinitis pigmentosa
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Encouraging preliminary Phase I/II data in retinitis pigmentosa
ReNeuron Group plc (RENE:LON) | 0 0 0.0% | Mkt Cap: 1.74m
- Published:
20 Feb 2019 -
Author:
Dr Jens Lindqvist -
Pages:
4
Today ReNeuron released encouraging early Phase I/II efficacy data for its lead retinal cell therapy programme, Human Retinal Progenitor Cells (hRPC), demonstrating a clear visual acuity improvement in retinitis pigmentosa (RP) patients. RP is an inherited, blindness-causing degenerative eye disease, affecting approx. 100k patients in the US. For the vast majority of RP patients there is currently no treatment available, and there is a clear unmet need for a treatment to reverse disease progress ....